Evidence map›Paper›PMID 36052513›Full record

ReviewThe EMBO journal2022

Extracellular vesicles and particles impact the systemic landscape of cancer.

Serena Lucotti, Candia M Kenific, Haiying Zhang, David Lyden

Open access · greenAbstract readReview
In one paragraph

Review in The EMBO journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 118 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Serena Lucotti *Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-1318-4761
Candia M Kenific *Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-5018-304X
Haiying ZhangChildren's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-7158-2373
David LydenChildren's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-0193-4131
Cornell University · US

Funding

Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
Systemic regulation of metastasisR35CA232093 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LYDEN, DAVID CHARLES · 2018 to 2024
$7.0M
Tumor-derived extracellular vesicles in the pre-metastatic niche.R01CA207983 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI Yves A DeClerck · 2017 to 2026
$5.6M
Development and application of asymmetric-flow field-flow (AF4) technology in fractionation and characterization of exosome subpopulations and novel nanoveiscles in pancreatic cancer modelR01CA218513 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jacob Geri, DAVID CHARLES LYDEN · 2017 to 2026
$4.3M
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDRU54CA163117 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI YU, HUA E · 2011 to 2015
$2.7M
NCI NIH HHS R01 CA207983NCI NIH HHS R01 CA218513NCI NIH HHS R35 CA232093NCI NIH HHS U01 CA210240NCI NIH HHS U54 CA163117
6 · The paper itself

Abstract

Intercellular cross talk between cancer cells and stromal and immune cells is essential for tumor progression and metastasis. Extracellular vesicles and particles (EVPs) are a heterogeneous class of secreted messengers that carry bioactive molecules and that have been shown to be crucial for this cell-cell communication. Here, we highlight the multifaceted roles of EVPs in cancer. Functionally, transfer of EVP cargo between cells influences tumor cell growth and invasion, alters immune cell composition and function, and contributes to stromal cell activation. These EVP-mediated changes impact local tumor progression, foster cultivation of pre-metastatic niches at distant organ-specific sites, and mediate systemic effects of cancer. Furthermore, we discuss how exploiting the highly selective enrichment of molecules within EVPs has profound implications for advancing diagnostic and prognostic biomarker development and for improving therapy delivery in cancer patients. Altogether, these investigations into the role of EVPs in cancer have led to discoveries that hold great promise for improving cancer patient care and outcome.

Indexed as

Extracellular VesiclesNeoplasmsCell CommunicationHumansImmunotherapyTumor Microenvironmentbiomarkerscancerextracellular vesicles and particlesmetastasistherapeutic deliverables

Identifiers

PMID36052513
PMCPMC9475536
OpenAlexW4294193220

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.